An animal model of differential genetic risk for methamphetamine intake by Tamara J. Phillips & Shkelzen Shabani
REVIEW
published: 23 September 2015
doi: 10.3389/fnins.2015.00327
Frontiers in Neuroscience | www.frontiersin.org 1 September 2015 | Volume 9 | Article 327
Edited by:
Juan J. Canales,
University of Leicester, UK
Reviewed by:
Deborah Baro,
Georgia State University, USA
Chamindi Seneviratne,
University of Maryland, USA
*Correspondence:
Tamara J. Phillips,
VA Portland Health Care System,
R&D32, 3710 SW US Veterans
Hospital Rd., Portland,
OR 97239, USA
phillipt@ohsu.edu
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neuroscience
Received: 01 June 2015
Accepted: 31 August 2015
Published: 23 September 2015
Citation:
Phillips TJ and Shabani S (2015) An
animal model of differential genetic risk
for methamphetamine intake.
Front. Neurosci. 9:327.
doi: 10.3389/fnins.2015.00327
An animal model of differential
genetic risk for methamphetamine
intake
Tamara J. Phillips 1, 2* and Shkelzen Shabani 3
1 VA Portland Health Care System, Portland, OR, USA, 2Department of Behavioral Neuroscience and Methamphetamine
Abuse Research Center, Oregon Health & Science University, Portland, OR, USA, 3Department of Biology, Minot State
University, Minot, ND, USA
The question of whether genetic factors contribute to risk for methamphetamine (MA) use
and dependence has not been intensively investigated. Compared to human populations,
genetic animal models offer the advantages of control over genetic family history and
drug exposure. Using selective breeding, we created lines of mice that differ in genetic
risk for voluntary MA intake and identified the chromosomal addresses of contributory
genes. A quantitative trait locus was identified on chromosome 10 that accounts for
more than 50% of the genetic variance in MA intake in the selected mouse lines. In
addition, behavioral and physiological screening identified differences corresponding
with risk for MA intake that have generated hypotheses that are testable in humans.
Heightened sensitivity to aversive and certain physiological effects of MA, such as
MA-induced reduction in body temperature, are hallmarks of mice bred for lowMA intake.
Furthermore, unlike MA-avoiding mice, MA-preferring mice are sensitive to rewarding
and reinforcing MA effects, and to MA-induced increases in brain extracellular dopamine
levels. Gene expression analyses implicate the importance of a network enriched in
transcription factor genes, some of which regulate the mu opioid receptor gene, Oprm1,
in risk for MA use. Neuroimmune factors appear to play a role in differential response
to MA between the mice bred for high and low intake. In addition, chromosome 10
candidate gene studies provide strong support for a trace amine-associated receptor
1 gene, Taar1, polymorphism in risk for MA intake. MA is a trace amine-associated
receptor 1 (TAAR1) agonist, and a non-functional Taar1 allele segregates with high
MA consumption. Thus, reduced TAAR1 function has the potential to increase risk for
MA use. Overall, existing findings support the MA drinking lines as a powerful model
for identifying genetic factors involved in determining risk for harmful MA use. Future
directions include the development of a binge model of MA intake, examining the effect
of withdrawal from chronic MA on MA intake, and studying potential Taar1 gene × gene
and gene × environment interactions. These and other studies are intended to improve
our genetic model with regard to its translational value to human addiction.
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Introduction
Methamphetamine (MA) is a highly addictive and potent
psychostimulant drug. The 2012 National Survey on Drug Use
and Health reported that∼5% of the population (over 12 million
people) has tried MA at least once. Addiction has been described
as a chronic, relapsing disease that is associated with long-term
neurological changes as a result of chronic drug use. Compulsive
drug seeking, despite negative consequences, is a hallmark (Joffe
et al., 2014). Not all individuals who try MA develop a pattern
of use that can be characterized as addiction. However, for those
that do, adverse physical, cognitive, and psychological effects are
likely to be experienced (Herbeck et al., 2013; Panenka et al., 2013;
Astarita et al., 2015). Risk for higher levels of MA use may have a
genetic component that we do not yet fully understand.
The euphoric and other rewarding effects of MA are likely
factors that underlie its addiction potential. In fact, MA can
increase brain dopamine (DA) levels, as well as serotonin and
norepinephrine levels, and thereby have an impact on brain
circuitry underlying the experience of reward (Fleckenstein et al.,
2007). However, some acute effects of MA are also likely to be
experienced as aversive. For example, MA can increase heart
rate and blood pressure, and can activate the “stress axis,” which
is involved in the flight or fight reaction to stressors and in
maintaining homeostasis (Polesskaya et al., 2011; Rusyniak et al.,
2012; Zuloaga et al., 2015). Sensitivity to rewarding effects of MA
that could increase risk for continued MA use may be countered,
in some individuals, by sensitivity to physiological effects that are
experienced as aversive. Thus, examination of both types of MA
effects, and their balance (Cruickshank and Dyer, 2009; Davis
and Riley, 2010), is important in identifying individuals who are
at greatest risk for MA addiction. Furthermore, identification of
genetic factors that influence sensitivity to these effects would
suggest important prevention and treatment targets.
Genetic Factors and Risk for MA Addiction
Human Data
Data from family, twin and adoption studies overwhelmingly
indicate that risk for substance abuse has a heritable component
(Kendler et al., 2003; Ystrom et al., 2014). Environment is also
important (McGue et al., 2000); however, in an analysis of six
classes of illicit substances, shared environment had a greater
impact on use than on abuse/dependence (Kendler et al., 2003).
Furthermore, although parent-offspring transmission involves
both environmental and genetic influences, genetic factors
appear to have a stronger role (Kendler et al., 2015), and some
findings indicate that the heritable influence is not substance-
specific (Kendler et al., 2003, 2015; Uhl et al., 2008). A number of
candidate genes have been nominated for further study for their
potential association with amphetamine (AMPH) sensitivity
(Hart et al., 2012) or a MA use disorder (Aoyama et al., 2006;
Bousman et al., 2009), though none have yet been confirmed.
Far less research has been done in this area for AMPHs than
for some other addictive substances, such as alcohol and nicotine
(e.g., Enoch, 2013; Loukola et al., 2014; Samochowiec et al., 2014;
Wen et al., 2014; Bühler et al., 2015). One logical reason for this
is that MA abuse has existed for less time, and another is that
the population size for MA abuse is smaller, making it difficult
to obtain adequate sample sizes for genome-wide association
studies.
Animal Data
In 2008, we reviewed the existing behavioral genetics literature
on addiction-related AMPH and MA effects (Phillips et al.,
2008). We found that the relevant literature consisted of a large
number of studies using single gene knockout mice and that
traits related to sensitivity to various effects of AMPHs were
well-represented, but the literature was lacking in the area of
reward- and consumption-related traits. Since then, a few studies
in this area have emerged. For example, genetic deletion of
two types of melatonin receptors was found to eliminate MA-
induced conditioned place preference (CPP), suggesting a role
in MA-related reward (Clough et al., 2014). Mice lacking the
neurotrophic factor, pleiotrophin, developed normal AMPH-
induced CPP that was sustained for a longer period of time
than in their WT counterparts (Gramage et al., 2010; Martin
et al., 2013). Increased expression of glial cell line-derived
neurotrophic factor in the striatum of mice reduced intravenous
self-administration of MA and cue-induced reinstatement of MA
seeking behavior (Yan et al., 2013). Some recent papers have
also reported genome-wide profiling of MA-induced effects. An
advanced intercross mouse line was used in a genetic analysis
of sensitivity to the acute stimulant effects of MA (Parker et al.,
2012) and 7 genome-wide significant quantitative trait loci (QTL)
were mapped (Parker et al., 2012). Cadet et al. (2013) identified
MA-regulated genes in the rat striatum and documented MA
effects on histone acetylation. Mulligan et al. (2013) focused on
the regulation of micro-RNA biogenesis genes in the brain across
multiple drugs of abuse including MA, and found roles in several
behavioral phenotypes. However, none of these genome-wide
analyses have been for MA-consumption related traits, for which
genetic mouse models have been lacking, whereas such models
are plentiful for alcohol (e.g., Morozova et al., 2012; Barr, 2013;
Becker, 2013; Crabbe, 2014a,b). To address this deficiency, we
took the lead from models created for alcohol consumption and
created an animal model of genetically-determined differences
in voluntary MA intake. Tables 1, 2 summarizes our published
findings so far.
Development of an Animal Model of
Genetic Risk for MA Intake
Intravenous operant self-administration has been considered
the gold standard for modeling human drug use in rodents,
because several features of addiction can be assessed, including
acquisition of drug use, strength of motivation, and relapse-
like behavior in response to drug-associated cues, stressors and
the drug itself (Nawata et al., 2012; Ma et al., 2013; Sharpe
et al., 2015). However, this method is not conducive to testing
the number of animals required for a selective breeding project
(∼600 animals for a short-term selective breeding project; 120
animals per generation). We created selected lines for high
and low MA intake using a voluntary drinking procedure
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TABLE 1 | Published MA traits characterized in the MA drinking lines.
Trait Drug dose Results References
MA drinking; 2-bc 18-h 20, 40 mg/l MAHDR-1 > MALDR-1 Wheeler et al., 2009
MA drinking; 2-bc 18-h 20, 40 mg/l MAHDR-2 > MALDR-2 Shabani et al., 2011
MA drinking; 2-bc 18-h 20, 40 mg/l MAHDR-3 > MALDR-3 Harkness et al., 2015
MA drinking; 2-bc 4-h; lickometer 20, 40, 80 mg/l MAHDR-2 > MALDR-2 Eastwood et al., 2014
MA blood levels after 2-bc 4-h 20, 40 mg/l MAHDR-2 > MALDR-2 Eastwood et al., 2014
Operant ICV MA self-administration 0.1–2.5 ug/infusion MAHDR-1 > MALDR-1 Shabani et al., 2012a
Operant oral MA self-administration 20, 40 mg/l MAHDR-2 > MALDR-2 Shabani et al., 2012a
MA-induced CPP: Drug-free CPP test 0.5mg/kg Preference only in MAHDR-1 Wheeler et al., 2009
MA-induced CPP: Drug-present CPP test 0.5mg/kg Preference only in MAHDR-1 Wheeler et al., 2009
MA-induced CPP: Drug-free CPP test 0.5, 2, 4mg/kg Preference only in MAHDR-2 Shabani et al., 2011
MA-induced CPP: Drug-present CPP test 0.5, 2, 4mg/kg MAHDR-2 preference; MALDR-2 aversion Shabani et al., 2011
MA-induced locomotor stimulation: acute 0.5, 2, 4mg/kg MAHDR-2 = MALDR-2 Shabani et al., 2011
MA-induced locomotor sensitization 0.5, 2, 4mg/kg MAHDR-2 > MALDR-2 Shabani et al., 2011
MA-induced CPA 2, 4mg/kg MAHDR-2 < MALDR-2 Shabani et al., 2012b
MA-induced CTA 1, 2mg/kg CTA only in MALDR-1 Wheeler et al., 2009
MA-induced CTA 1, 2, 4mg/kg CTA only in MALDR-2 Shabani et al., 2012b
MA-induced hyperthermia 1, 2, 4, 8, 16mg/kg Hyperthermia only in MAHDR-2 Harkness et al., 2015
MA-induced hyperthermia 1, 2, 4, 8, 16mg/kg MAHDR-3 > MALDR-3 Harkness et al., 2015
MA-induced hypothermia 1, 2, 4mg/kg Hypothermia only in MALDR-2 Harkness et al., 2015
MA-induced hypothermia 2, 4mg/kg Hypothermia only in MALDR-3 Harkness et al., 2015
MA-induced behavioral inhibition 0.5, 1, 2, 4mg/kg MAHDR-1 = MALDR-1 Moschak et al., 2012
MA drinking on circadian period length 25, 50 mg/l MAHDR-2 < MALDR-2 Olsen et al., 2013
MA-induced DA release in NAc 2mg/kg MAHDR-2 = MALDR-2 Lominac et al., 2014
MA-induced 5-HT release in NAc 2mg/kg MAHDR-2 = MALDR-2 Lominac et al., 2014
MA-induced DA release in mPFC 2mg/kg MAHDR-2 > MALDR-2 Lominac et al., 2014
MA-induced 5-HT release in mPFC 2mg/kg MAHDR-2 < MALDR-2 Lominac et al., 2014
2-bc, 2-bottle choice; 5-HT, serotonin; CPP, conditioned place preference; CPA, conditioned place aversion; CTA, conditioned taste aversion; DA, dopamine; ICV, intracerebroventricular;
MA, methamphetamine; MAHDR, methamphetamine high drinking; MALDR, methamphetamine low drinking; mPFC, medial prefrontal cortex; NAc, nucleus accumbens.
(Wheeler et al., 2009; Shabani et al., 2011). Justification for the
approach can be found in our previous publications and model
validation studies are described below. Relevant to the model is
that humans administer MA via the oral route, MA is readily
absorbed via the digestive tract, and its use via this route can lead
to dependence that is similar to that seen when it is administered
intravenously or via the nasal route (Sulzer et al., 2005; United
Nations Office on Drugs and Crime, 2010).
The F2 cross of the C57BL/6J (B6) and DBA/2J (D2) inbred
mouse strains were the originating population of mice used to
develop the MA high drinking (MAHDR) and MA low drinking
(MALDR) lines. This cross was chosen to allow comparison
of our genetic results to those for MA and other drug traits
examined previously in B6 and D2 mice or in other genetic
models derived from them, such as recombinant inbred strains
(Grisel et al., 1997; Phillips et al., 1998; Bergeson et al., 2001;
Janowsky et al., 2001; Kirstein et al., 2002; Fehr et al., 2005; Palmer
et al., 2006; DuBose et al., 2013). Two-bottle choice MA drinking
was measured in 120 F2 mice. The mice were individually housed
and allowed during a 48-h period to consume fluid from 25-ml
graduated cylinders fitted with stoppers and ball-bearing sipper
tubes. For the next 4 days, they were offered a tube containing
tap water and another containing 20mg of MA per liter of tap
water (20mg/l) for an 18-h period, beginning 3 h before the dark
cycle began. On the subsequent 4 days, the MA concentration
offered was increased to 40 mg/l. The relative position of the MA
tube to the water tube was alternated every 2 days. During the
additional 6 h of each day, themice had free access to a single tube
containing tap water. Food was available at all times. Drinking
volumes for all tubes were measured at the beginning and end of
the 18-h period and also for the 6-h water-only periods. These
data were used to calculatemg of MA consumed per kg of body
weight and preference for the MA-containing solution, which
was calculated by dividing the volume (ml at an accuracy of
0.2ml) consumed from the MA tube by total volume consumed
from the water andMA tubes during the 18-h period. To identify
the animals that consumed the most and the least MA, average
amount consumed in mg/kg on days 2 and 4, when the 40mg/l
concentration was offered, was used. Days 2 and 4 were second
days after a MA tube position switch and use of data from these
days reduces variability in volume intake associated with the
animal having to locate the MA-containing tube.
The decision to offer MA for 18 vs. 24 h a day followed a
colleague’s advice; he suggested that anorectic-like effects were
less likely to occur with sub-chronic access. However, we also
wanted to provide longer periods of access to MA, to allow
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TABLE 2 | Published non-MA traits characterized in the MA drinking lines.
Trait Drug dose Results References
Quinine drinking; 2-bc 24-h 0.015, 0.03mM MAHDR-1 = MALDR-1 Wheeler et al., 2009
Quinine drinking; 2-bc 24-h 0.015, 0.03mM MAHDR-2 = MALDR-2 Shabani et al., 2011
Saccharin drinking; 2-bc 24-h 0.033, 0.066% MAHDR-1 = MALDR-1 Wheeler et al., 2009
Saccharin drinking; 2-bc 24-h 0.033, 0.066% MAHDR-2 = MALDR-2 Shabani et al., 2011
KCl drinking; 2-bc 24-h 100, 200mM MAHDR-1 = MALDR-1 Wheeler et al., 2009
KCl drinking; 2-bc 24-h 100, 200mM MAHDR-2 = MALDR-2 Shabani et al., 2011
Voluntary morphine intake 2-bc 24-h 0.3, 0.7, 1mg/ml MAHDR-2 < MALDR-2 Eastwood and Phillips, 2014
Basal locomotor activity saline MAHDR-1 = MALDR-1 Wheeler et al., 2009
Basal locomotor activity saline MAHDR-2 = MALDR-2 Shabani et al., 2011
COC-induced CPP: Drug-free CPP test 10mg/kg MAHDR-2 = MALDR-2 Gubner et al., 2013
COC-induced locomotor stimulation: acute 5, 10, 20, 30mg/kg MAHDR-2 = MALDR-2 Gubner et al., 2013
COC-induced CTA 15, 30mg/kg MAHDR-2 = MALDR-2 Gubner et al., 2013
Ethanol-induced hypothermia 2, 4 g/kg MAHDR-2 = MALDR-2 Harkness et al., 2015
Novel object recognition naive MAHDR-2 = MALDR-2 Olsen et al., 2013
Spatial memory retention naive MAHDR-2 < MALDR-2 Olsen et al., 2013
Fear conditioning naive MAHDR-2 = MALDR-2 Olsen et al., 2013
Fentanyl analgesic effects 0.05, 0.1, 0.2, 0.4mg/kg MAHDR-2 = MALDR-2 Eastwood and Phillips, 2012
Basal locomotor activity saline MAHDR-2 < MALDR-2 Eastwood and Phillips, 2012
Fentanyl locomotor effects 0.1, 0.2, 0.4mg/kg MAHDR-2 < MALDR-2 Eastwood and Phillips, 2012
Morphine locomotor effects 10, 20, 30mg/kg MAHDR-2 < MALDR-2 Eastwood and Phillips, 2012
2-bc, 2-bottle choice; COC, cocaine; CPP, conditioned place preference; CTA, conditioned taste aversion; KCl, potassium chloride; MA, methamphetamine; MAHDR, methamphetamine
high drinking; MALDR, methamphetamine low drinking.
animals to consume relatively high amounts. Other research also
indicates that longer access periods result in higher levels of MA
self-administration in rats (Recinto et al., 2012). We have not
yet published data comparing intake for 18 vs. 24 h a day in the
MA drinking (MADR) lines, nor have we examined the impact of
differing withdrawal periods, though such studies are planned.
We have completed the selective breeding of 3 sets ofMAHDR
and MALDR lines. Response to selection across generations
has been published for two sets of these lines (Wheeler et al.,
2009; Shabani et al., 2011) and results are comparable for the
third set (Harkness et al., 2015). These replicate sets of lines
were consecutively created, at an ∼2-year interval. There is high
consistency of the selective breeding results. There are several
advantages to producing consecutive vs. simultaneous replicate
lines. These include a smaller colony space requirement, lower
level resources spread across time, and the ability to perform
identical replication studies, as well as extend studies based
on results in former lines. One example of such an extension
is a study that we recently performed to examine pattern of
MA intake over time in the replicate 2 MAHDR and MALDR
lines (Eastwood et al., 2014). A lickometer system was used
to determine pattern of MA drinking in addition to amount
consumed. Pattern variables analyzed were latency to first bout
of licks, the number of bouts, bout length, and interbout interval.
A bout was defined as a series of 20 or more licks separated
by less than 1min. Similar to results in an operant oral self-
administration procedure described later in this paper (Shabani
et al., 2012a), the MADR lines did not differ in MA consumption
on the first day that a 20 mg/l MA solution was offered. However,
MA consumption diverged after the second day and diverged
even more with increases in MA concentration (mice were tested
at concentrations of 20, 40, and 80mg/l in this study). MAHDR
mice escalated their MA consumption with each increase of
MA concentration, but MALDR consumed negligible amounts.
Furthermore, MA blood levels measured after a 2 and 4 h MA
drinking session in a 2-bottle choice procedure matched the MA
drinking patterns in theMADR lines. Latency to first bout, which
can be viewed as an appetitive behavior, was similar at first,
but after the first day it diverged in a similar fashion to MA
consumption. Shyness to lick the sipper with the MA solution
and subsequent lower MA consumption by MALDR mice is
an indication of rapid development of MA aversion. All other
patterns of consumption behaviors measured via lickometer
supported the MA consumption data and the difference between
the MAHDR and MALDR lines.
In the sections below, we describe additional research that
has been performed in these lines, which provides evidence of
their usefulness as a genetic animal model of both genetic risk
for and genetic protection fromMA use. We also discuss at some
length, the potential role of the trace amine-associated receptor
1 (TAAR1) in the difference in MA intake and several other
divergent MA-related behavioral traits.
MA Reward and Aversion Sensitivity in MAHDR
and MALDR Mice
Important advances in our understanding of the genetic
contribution to a number of MA addiction-related traits have
been made using our genetic mouse model of differential MA
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consumption. Robust divergence in voluntary MA intake in the
MADR lines has been matched with significant divergence in
sensitivity to the rewarding and aversive effects of MA. In two
independently selectively bred, replicate sets ofMADR lines,MA-
induced CPP has been measured using well established methods
in which MA was paired with a distinctive tactile cue and then
the preference for that cue was later examined, both in the
absence and in the presence of MA treatment. MAHDR mice
exhibited MA-induced CPP in a drug-free CPP test (saline was
administered prior to the test); whereas, no preference for MA-
associated cues was seen in MALDR mice, regardless of the
conditioning dose (Wheeler et al., 2009; Shabani et al., 2011). The
divergence in MA-induced motivational responses between the
MADR lines was especially apparent when they were tested in
a drug-present CPP test (animals are given the same MA dose
they had received during conditioning, immediately before the
preference test). The MA dose of 0.5mg/kg induced robust CPP
in MAHDR mice, whereas place aversion was seen in MALDR
mice regardless of dose (0.5, 2, and 4mg/kg). There were no
differences in locomotor activity between the MADR lines after
treatment with the 0.5mg/kg MA dose on the drug-present
test day; thus, differential activation by MA could not account
for their difference in the expression of preference/aversion
at this dose. At 2 and 4mg/kg MA, locomotor responses
were higher in MAHDR than MALDR mice; this could reflect
a sensitized response to repeated administration of MA, as
MAHDRmice exhibited greater sensitization than MALDRmice
after repeated administration ofMA during theMA conditioning
days, although the difference was significant only for the 4mg/kg
dose (Shabani et al., 2011). Activation could have affected
expression of a CPP. For ethanol, higher level of locomotor
behavior is related to the reduced expression of CPP (Gremel
and Cunningham, 2007; Cunningham, 2014), and the apparent
magnitude of CPP was somewhat smaller in MAHDR mice
for the higher MA doses. When we directly examined this for
individual animals on the drug-present test data, we found that
higher levels of activity were associated with lower expression
of both preference and aversion. Despite this relationship at
the level of individual mice, the MALDR mice expressed clear
place aversion after treatment with all 3 MA doses, based on
group means. It is also possible that unconditioned aversive
effects of MA during conditioning and during testing (such as
the hypothermia experienced in MALDR, but not MAHDR,
mice; Harkness et al., 2015) enhanced the conditioned aversive
responses seen in these mice. These data reflect three important
points: (1) that both MADR lines are able to discriminate MA-
conditioned cues; (2) that responses to conditioned cues are state-
dependent; and (3) that significant conditioned aversion was seen
in MALDR mice in the drug-present, but not drug-free state.
Differential sensitivity to aversive effects of MA between the
MADR lines has been further confirmed in studies designed
to be more sensitive at detecting drug-induced aversion. These
procedures are referred to as conditioned taste aversion (CTA)
and conditioned place aversion (CPA). In both procedures, MA
is administered immediately after cue exposure (i.e., a novel taste
for CTA and a tactile cue for CPA), rather than before exposure,
as in the CPP procedure. It has been suggested that aversion
is seen under these conditions, because initial drug effects (e.g.,
transition from a normal to intoxicated state), in general, are
aversive (Hunt and Amit, 1987; Cunningham et al., 2003, 2006);
for example, specific physiological responses that are temporally
closer to the cue exposure than other more rewarding effects that
take longer to manifest. In these studies (Shabani et al., 2012b),
MALDR mice exhibited MA-induced CTA at doses as low as
1mg/kg, whereas no CTA was seen in MAHDR mice up to a
dose of 4mg/kg, the highest dose we have tested. MALDR mice
also exhibited CPA at a lower MA dose (2mg/kg) than MAHDR
mice (4mg/kg). These differences are not likely accounted for
by MA pharmacodynamics. MAHDR mice reached higher MA
blood levels than MALDR mice at 15min post 2mg/kg MA
injection, but the MA clearance curves for the two lines were
similar (Shabani et al., 2012b). Insensitivity to aversive effects of
MA in MAHDR mice appears to be unique to MA, because they
did exhibit cocaine-induced CTA (Gubner et al., 2013). The traits
described above for which the MADR lines differ, are genetically
correlated with MA intake. This suggests some common genetic
regulation across these traits, and indicates that at least some
of the genetic factors that influence sensitivity to conditioned
rewarding and aversive effects of MA also have an impact on
MA consumption and seeking (drug-associated cue seeking in
the CPP test has been sometimes interpreted as drug seeking).
Data for cocaine indicate that learning deficits were not involved
in the absence of conditioned responses in either of the lines
and that genetic factors influencing these MA-related traits do
not influence some similar responses to cocaine. For example,
similar levels of both cocaine-induced CPP and CTA were seen
in MAHDR and MALDR mice (Gubner et al., 2013) and mice
of both lines exhibited equivalent learning in operant procedures
(Shabani et al., 2012a). It should be noted that there may be an
innate difference between the lines in spatial memory retention,
as indicated by a deficit in MAHDR mice in the Morris water
maze test (Olsen et al., 2013); however, testing in an additional
set of MADR lines is needed to examine replicability of this result
and its association with risk for MA consumption.
Studies in the MADR lines strongly support the view that
higher MA consumption, which reflects greater vulnerability to
continue drug use beyond initial experimentation, is genetically
related to greater sensitivity to the rewarding and reduced
sensitivity to the aversive effects of the drug. This relationship
does not appear to be unique to MA. For example, rat strains
with high sensitivity to aversive effects of morphine, ethanol,
or nicotine display lower self-administration of those drugs
compared to strains with low sensitivity to the aversive effects
(Lancellotti et al., 2001; Sánchez-Cardoso et al., 2007; Davis
and Riley, 2010). Similarly, rat strains with higher sensitivity to
rewarding effects of cocaine (Kosten et al., 1994) acquire cocaine
self-administration more rapidly (Kosten et al., 1997). Because
these studies utilized only 2 rat strains, definitive conclusions
about genetic relationships cannot be drawn. However, studies
in larger panels of inbred mouse strains and in selected rat and
mouse lines bred for high and low ethanol intake consistently
indicate a genetic relationship between ethanol drinking and
sensitivity to aversive effects of ethanol (Froehlich et al., 1988;
Chester et al., 2003; Green and Grahame, 2008; Cunningham,
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2014; Barkley-Levenson et al., 2015), though not in all cases (see
Green and Grahame, 2008). Data are less consistent with regard
to the relationship between sensitivity to ethanol reward and
ethanol intake (Grahame et al., 1999; Phillips et al., 2005; Green
and Grahame, 2008; Cunningham, 2014). Some discrepancy may
relate to differences in genetic background of the models used in
these studies and additional research is needed to examine these
relationships for MA in genotypes other than those derived from
the B6 and D2 inbred mouse strains.
MA Reinforcement
In addiction disorders, drug consumption or “taking” patterns
interact with drug seeking, an appetitive behavior, such that
binge-abstinence patterns of drug intake, over time, enhance
appetitive behavior (Roberts et al., 2013). However, there are
methods that allow consummatory and appetitive behaviors to
be considered independently and they appear to be regulated
by at least some separate neural circuits. For example, in
some operant oral ethanol self-administration procedures, the
instrumental behavior, in the form of lever pressing that
triggers access to ethanol, is separated from the consummatory
behavior, voluntary drinking of the ethanol. Pharmacological
manipulations that affect the consummatory behavior do
not necessarily affect the appetitive behavior (Czachowski
et al., 2002; Ford et al., 2007) and vice versa (Czachowski
et al., 2002). Evidence indicating independent regulation of
appetitive and consummatory behaviors has been generated for
psychostimulants as well, though unlike the ethanol studies,
operant intravenous self-administration procedures were used
(Roberts et al., 2013).
To examine bothMA appetitive and consummatory behaviors
in our genetic model of differential MA intake, we developed an
operant oral MA self-administration procedure (Shabani et al.,
2012a). Active lever pressing triggered a light cue above the lever,
turned off the house light, and lowered a sipper tube into the
chamber for a limited period of time, from which the animal
could drink. Pressing of an inactive lever had no consequence.
Initially animals were reinforced with a 0.2% saccharin solution
on a fixed ratio 1 (FR1) schedule (animals gained access to the
saccharin solution each time they pressed the active lever), and
then MA was added into the saccharin solution in a stepwise
fashion (up to 40 mg/l MA, the highest concentration used
during selective breeding). The schedule was then changed to
FR2 (animals had to press the lever twice to gain access to the
drinking tube) and saccharin was faded completely out of theMA
solution in a stepwise fashion, so that it was ultimately presented
in water alone (no saccharin). A control group was maintained
on the same schedule of reinforcement and animals in that
group could press the active lever to obtain access to the same
solutions, minus MA. Therefore, the control group was pressing
only for water at the end of the study, and provided information
about operant behavior in the absence of either saccharin or
MA reinforcement. Similar to results for the lickometer study
(Eastwood et al., 2014), the two MADR lines did not differ
in MA consumption on the first day that MA was added to
the solution. However, MA consumption diverged immediately
thereafter, with MAHDR mice consuming significantly more
MA than MALDR mice. With regard to the appetitive behavior
of active lever pressing, there was little difference between the
MADR lines when the FR1 schedule was in place; however,
MAHDR mice approximately doubled their responding for the
MA-containing solution when the demand for MA access was
increased by instating an FR2 schedule, whereas MALDR mice
retained a lower response rate. The lines of mice did not differ in
response rate on the inactive lever, which remained low. These
data led to two significant conclusions: (1) pharmacological
effects appear to account for divergence in MA consumption
in the MADR lines (since the lines consumed similar amounts
initially, it is not likely that taste of the MA solution accounted
for the subsequent line difference in intake), and (2) genetic risk
for increased MA intake is associated with increased appetitive
responding for MA; i.e., greater MA reinforcement. We have also
confirmed that MAHDR mice will self-administer MA using an
operant intracerebroventricular self-administration procedure,
which bypasses the oral route, whereas MALDR mice do not
acquire this behavior (see Shabani et al., 2012a). Finally, solution
intake in the control group declined with saccharin removal.
When the schedule was transitioned to FR2, theMALDR, but not
MAHDR, control group increased their appetitive responding.
This suggests that the MALDR line is more sensitive to the
reinforcing effects of natural rewards than the MAHDR line, as
they continued to respond for cues associated with the tube that
had contained saccharin without MA, even after saccharin had
been faded out. Reduced sensitivity to natural rewards could be a
potential factor driving higher drug intake in the MAHDR line.
One other procedure that we used to examine reinforcing
efficacy was tracking of the reinforced lever after reversal of its
location with the non-reinforced lever. MAHDR mice exhibited
clear tracking of the MA-reinforced lever and maintained
significantly higher MA-reinforced presses on the lever in the
new location than on the non-reinforced lever, compared to
the MALDR mice. On the other hand, the MALDR control
group exhibited stronger tracking of lever reversal than did the
MAHDR control group. The lever reversal test measures seeking
behavior independent of consummatory behavior, because there
is no change in location or mode of reinforcer presentation,
and thus, consummatory behavior is minimally affected. In
retrospect, to measure MA reinforcement we could also have
omitted MA from the solution during the lever reversal
procedure. This would have been more like what the control
group experienced, since saccharin had been completely faded
from the solution, and would provide a test in which seeking
behavior is unfettered by postingestive effects of MA. A
progressive ratio schedule, in which the behavioral demand
is increased over time (i.e., the FR requirement is increased
until the animal stops pressing for drug access), is another
method that we plan to use in a future study to confirm our
findings.
Operant methods have also been used to test the hypothesis
that the difference in MA consumption between the MADR lines
is related to a difference in impulsive-like behavior. To examine
this, a go/no-go task was employed in which mice were trained
to perform a nose-poke task to gain access to sucrose, according
to specific signaled (cued) requirements (Moschak et al., 2012).
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Responding at appropriate and inappropriate times was recorded
and provided measures of false alarms, hits, and behavioral
inhibition (i.e., the ability to withhold responding during the
precue period). The MADR lines did not differ in behavioral
inhibition when untreated or when treated withMA. In the drug-
naïve state, MALDR mice did exhibit a greater hit rate to the
visual “go” cue, suggesting that they were more responsive to
the cue. Whether salience or visual acuity had a role in this
difference is currently unknown; however, a relationship between
impulsive-like behavior and genetic susceptibility to MA intake
was not found.
Finally, to our knowledge, this is the first genetic animal model
specifically created for a trait related to MA intake. However,
lines of rats bred for high (HiS) and low (LoS) saccharin intake
deserve mention (Dess and Minor, 1996), based on evidence of
the involvement of natural reward pathways in the effects of
drugs of abuse (Joffe et al., 2014) and of predictability of level of
AMPH self-administration from individual differences in sucrose
intake (DeSousa et al., 2000). Compared to the LoS line, the HiS
line exhibits a higher level of operant responding for sucrose
(Gosnell et al., 2010), consumes more ethanol (Dess et al., 1998),
self-administers more cocaine (Morgan et al., 2005), and shows
more rapid escalation of cocaine intake (Perry et al., 2006). These
data support a link between avidity for a natural reward and for
several drugs of abuse, but to our knowledge, these lines have not
been studied for their avidity for AMPH or MA. Our operant
data in theMADR lines suggest the opposite relationship between
avidity for saccharin and MA (Shabani et al., 2012a).
Physiological Responses to MA
MA is a powerful sympathomimetic with dose-dependent effects
on body temperature, heart rate, and blood pressure, and thus,
it disrupts homeostasis (Rusyniak et al., 2012; Harkness et al.,
2015). MA may produce its effects on body temperature through
both central nervous system and peripheral targets (Matsumoto
et al., 2014). Our recent data reveal a highly significant divergence
inMA-induced thermic response betweenMAHDR andMALDR
mice (Harkness et al., 2015). Lower doses of acutely administered
MA (1–4mg/kg) induced hypothermia in MALDR mice, an
effect not seen in MAHDR mice at any dose. Doses of MA
from 1 to 16mg/kg induced hyperthermia in MAHDR mice,
whereas hyperthermia was seen in one replicate line of MALDR
mice only after treatment with 16mg/kg MA. Our previous
published work indicates no difference in initial MA-induced
locomotor response between the two lines (Shabani et al., 2011);
therefore these differences in MA-induced thermic effects are
not likely accounted for by differences in overall locomotor
activity. Furthermore, animals are individually housed in small
chambers that restrict locomotor behavior. These chambers are
used to prevent changes in body temperature via heat exchange
between cagemates. Overall, these data indicate that MA-induced
hypothermia is associated with lower MA intake and may be
a protective physiological response. On the other hand, greater
sensitivity to the hyperthermic response to MA does not appear
to protect against MA consumption, and instead was associated
with greater risk for MA consumption.
Differential MA-induced activation of the sympathetic
nervous system could play a role in the difference between the
MADR lines in thermal response to MA. In a recent study
in anesthetized rats, MA infused into the medial prefrontal
cortex (mPFC) evoked interscapular brown adipose tissue
thermogenesis, a sympathetic nervous system-mediated effect
(Hassan et al., 2015). Furthermore, norepinephrine, but not DA,
infused into the mPFC mimicked the MA effect. MA increased
extracellular DA in the mPFC of MAHDR, but not MALDR,
mice (Lominac et al., 2014), whereas MA had no effect on
extracellular serotonin in the mPFC of MAHDR mice, but
increased extracellular serotonin in the mPFC of MALDR mice.
Neither of these effects of MAwas seen in the nucleus accumbens
(NAc). MA-induced extracellular norepinephrine levels have not
been measured in response to MA in these mice. Rats with their
adrenal glands removed failed to exhibit a hyperthermic response
to MA, but dexamethasone, a corticosterone-like drug, “rescued”
this MA-induced hyperthermic response (Makisumi et al., 1998).
Furthermore, sympathetic blockade via peripheral depletion of
catecholamines abolished the MA-induced hyperthermic effect.
Our mouse model provides a unique opportunity to determine
mechanisms of MA-induced thermic effects in the central
nervous system, as well as the peripheral nervous system and its
targets.
Because the MA-induced thermic responses occur rapidly
after injection, it is reasonable to assume that animals make
strong associations between the unconditioned physiological
effect and the unique cues used in conditioning studies.
Therefore, these physiological effects of MA could have a role
in the conditioned responses. For example, it is possible that
different behavioral outcomes are seen in the drug-present
and drug-free preference tests, in part, because MA-induced
physiological cues are missing during the drug-free CPP test.
Harkness et al. (2015) explored thermic responses to a single
acute bolus MA administration, whereas the behavioral response
in the drug-present CPP test was examined after repeated MA
administrations. Repeated MA administration in a rat model did
not diminish hyperthermic responses under similar conditions
to ours (Myles et al., 2008). However, hypothermic responses
were enhanced. In addition, MA-induced thermic effects can be
dependent on ambient temperature (Myles et al., 2008; Sabol
et al., 2013), which we have not yet explored, nor have we
explored other MA-induced sympathomimetic effects, such as
heart rate, breathing rate, and blood pressure, which could also
affect thermic responses and motivated behaviors.
Finally, another effect of MA that could impact risk for its
use, is its circadian rhythm disrupting effect (e.g., Pendergast
et al., 2013; Pendergast and Yamazaki, 2014). We examined the
free-running circadian period of the MADR lines and found
no difference in drug-naïve mice, but greater sensitivity in the
MALDR line to the effect of voluntarily consumed MA to
lengthen the circadian period. The MALDR line was significantly
more sensitive to this MA effect, although they consumed
significantly less MA than the MAHDR line. These data suggest
that MA effects on circadian rhythm may also be protective
against MA consumption (Olsen et al., 2013). We have not
examined whether circadian rhythm disturbance might alter MA
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intake, but a recent study by Doyle et al. (2015) reported that
MA consumption was increased in phase-shifted rats that had a
history of MA use.
Quantitative Trait Locus and Expression Analyses
The heritability of two-bottle choice MA consumption in the
replicate 1 and 2 lines was ∼0.35 (Wheeler et al., 2009; Shabani
et al., 2011), indicating that 35% of the variance in MA intake
can be attributed to genetic differences. In an initial study, we
examined the potential involvement of a select set of genes (384
chosen for their potential involvement in psychiatric disorders,
including addiction) by studying their expression levels in NAc
tissue from MA-naïve and MA-treated MAHDR and MALDR
mice. A quantitative PCR gene array (Mouse Mood Disorder
StellARray) was used. In MA-naïve mice, there were multiple
genes that were different in basal level of expression between the
selected lines, including serotonin and noradrenaline transporter
genes (but not DA transporter) and a metabotropic glutamate
receptor gene, as well as genes for adenylate cyclase activating
polypeptide 1, glutathione peroxidase 1, and others too numerous
to mention. Detailed results are presented in Wheeler et al.
(2009). In mice given an acute injection of 2mg/kg MA, a
dose that induces different reward- and aversion-related traits
in the MAHDR and MALDR lines, MA-induced changes in
gene expression were largely line-specific, but it is worth noting
that MA appeared to have the effect of altering expression to
counteract differences in basal expression level that were seen
between the lines.
Genes involved in apoptosis, immune response, and cytokine
signaling were enriched among those that were regulated by MA
in the MALDR line, whereas genes relevant to toll-like receptor
signaling were regulated by MA in the MAHDR line. Given
recent data suggesting that neuroimmune signaling plays a role
in biological processes associated with addiction (Cui et al., 2014;
Ray et al., 2014), studies are currently examining neuroimmune
responses to acute and repeated MA treatment at the level of
specific cytokines and chemokines to determine their potential
involvement in the difference inMA intake between theMAHDR
and MALDR lines.
To identify the chromosomal locations of influential genes,
QTL analysis was conducted (Belknap et al., 2013). QTLmapping
results were reproducible and indicated a large effect QTL on
chromosome 10 that accounts for more than 50% of the genetic
variance in MA consumption. There were also several genome-
wide significant QTLs on other chromosomes, which had
smaller magnitude effects than the chromosome 10 QTL. Also
described in this published paper are the results of microarray
gene expression (Affymetrix) analyses in MA-naïve MAHDR
and MALDR mice for 3 brain regions, the NAc, prefrontal
cortex, and ventral midbrain (including the substantia nigra and
ventral tegmental area). In the chromosome 10 QTL location,
there was similar clustering of differentially expressed probe
sets for the 3 brain regions, although the specific probe sets
making up those clusters differed among the brain regions. A
comparative network analysis was performed to identify groups
of differentially expressed genes with coordinated gene function,
and found a significant transcription factor rich subnetwork
that was functionally enriched for the regulation of apoptotic
processes that could have a role in neuroimmune signaling. This
supported further study of neuroimmune signaling involvement
in not only the effects of MA, but also in risk for MA use.
Behavioral MA-related Traits in the Progenitor
Strains of the MADR Lines
The B6 and D2 progenitor strain mice have been characterized
for some MA-related traits that are similar to those examined
in the MADR lines. D2 mice consumed more MA than B6
mice (Eastwood and Phillips, 2012), which is consistent with the
association of D2 alleles on chromosome 10 with high MA intake
(Belknap et al., 2013). Separate studies with B6 and D2 mice
have reported sensitivity to MA-induced CPP in both strains
(Cunningham and Noble, 1992; Thanos et al., 2010; Bryant
et al., 2012; Dobbs and Cunningham, 2014; Lominac et al.,
2014), and we have been unable to find a study that directly
compared these strains. Testing these strains in a CPP study
identical to ours would be important for determining whether
a progenitor strain difference exists that is comparable to our
MADR line difference. In that case, we would expect D2 mice to
exhibit greater sensitivity to MA-induced CPP, compared to B6
mice. With regard to MA effects on body temperature, D2 mice
exhibited an AMPH-induced hyperthermic response, whereas B6
mice exhibited greater hypothermia, and blunted MA-induced
hyperthermia (Seale et al., 1985), traits that are consistent with
the relationships found in the MADR lines. Recombinant inbred
strains were tested to determine whether the differential high
dose AMPH-induced hyperthermic response had a polygenic
influence. In fact, only two AMPH-induced thermic response
phenotypes were found, rather than a continuous distribution,
supporting the influence of a single gene. Results in another study
using D2 and B6 mice indicated little difference between the
strains. However, temperature was assessed at only a single time
point in that study (Grisel et al., 1997).
With regard to locomotor responses to MA or AMPH, in two
studies, somewhat larger initial stimulant responses, depending
on dose, were seen in B6, compared to D2 mice (Phillips et al.,
1994; McNamara et al., 2006). However, the Phillips et al. (1994)
study revealed a greater magnitude of sensitization to 1 and
2mg/kg MA in D2, compared to B6, mice (Phillips et al., 1994).
In another study, B6 mice did not exhibit significant AMPH-
induced locomotor activation at any dose, whereas significant
increases in locomotor behavior in response to some AMPH
doses, but locomotor depression in response to others was found
in D2 mice (Anisman et al., 1975). D2 and B6 strains from
a different vendor (i.e., Charles River, Italy) both exhibited
significant locomotor activation to 2.5mg/kg AMPH, but the
AMPH-induced locomotor response was lower in D2 than B6
mice (Zocchi et al., 1998; Ventura et al., 2004). Our data for
the MADR lines have not indicated any consistent differences
in sensitivity to the acute stimulant effects of MA. Furthermore,
gene mapping in lines of mice bred from the B6D2F2 for
differential sensitivity to the acute stimulant effects ofMA did not
identify a QTL on chromosome 10 (Kamens et al., 2005; Palmer
et al., 2005), nor did mapping in lines of mice bred from the
B6D2F2 for differential magnitude of MA-induced sensitization
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(Scibelli et al., 2011; Belknap et al., 2013). Therefore, if there
are differences between the MADR lines and their progenitor
strains in locomotor activation by MA, they may be unrelated to
polymorphic genes associated with the large effect QTL for MA
intake on chromosome 10.
Candidate Gene and Mechanism Studies
The Mu-opioid Receptor Gene, Oprm1
The chromosome 10 QTL has not yet been fine-mapped and the
interval includes a large number of genes. Included among them
is Oprm1, for which our microarray analysis identified greater
expression in prefrontal cortex tissue from MALDR, compared
to MAHDR, mice. D2 alleles are found at higher frequency
in MAHDR mice than MALDR mice in the chromosome 10
QTL region and thus, are associated with higher MA intake
(Belknap et al., 2013). Furthermore, D2 and B6 mice have been
found to differ in several opioid-related responses, including
sensitivity to the acute stimulant effects of morphine, sensitivity
to morphine-induced analgesia, and morphine intake (Belknap
et al., 1989, 1993; Berrettini et al., 1994a,b; Phillips et al., 1994;
Bergeson et al., 2001). We therefore performed a series of studies
designed to ascertain whether Oprm1 is a viable candidate as an
influential quantitative trait gene in our QTL region. MALDR
mice were found to be more sensitive than MAHDR mice to the
locomotor stimulating, but not analgesic, effects of mu opioid
receptor (MOP-r) agonist drugs (Eastwood and Phillips, 2012).
In addition, MALDRmice voluntarily consumed higher amounts
of morphine than MAHDR mice, and MOP-r agonists, but not
antagonists, reduced MA intake in MAHDR mice (Eastwood
and Phillips, 2014). Furthermore, we found higher MA intake in
D2 than in B6 mice, consistent with the largely D2 genotype of
MAHDRmice on chromosome 10 (Eastwood and Phillips, 2012).
These findings support genetic correlations between some opioid
drug responses andMA intake and thus, suggest common genetic
regulation of these traits. However, linkage as an explanation
for these results cannot currently be ruled out. The D2-like
Oprm1 allele may occur at higher frequency in the MAHDR
line because it is linked to the gene that influences MA intake,
resulting in these line-specific opioid responses. In fact, our
network analysis did not identifyOprm1 as a member of the gene
network regulating MA consumption, but when it was added
to the network, it exhibited regulation by several transcription
factor genes in the network (Belknap et al., 2013).
The Trace Amine-Associated Receptor 1 Gene, Taar1
Another gene within the chromosome 10 QTL confidence
interval is Taar1. Our recent data strongly suggest that it has
a significant role in MA drinking (Harkness et al., 2015). Our
interest in this gene was stimulated by information in existing
databases that indicated that the D2 progenitor of the MADR
lines possesses a non-synonymous mutation in Taar1, which we
subsequently determined codes for a non-functional receptor
(TAAR1). This polymorphism is unique to the D2 strain. A
paper published in 2010 (Vallender et al., 2010) detailed the
functional evolution of TAAR1 and concluded that Taar1 appears
to be under strong purifying selection across mammals, avians,
and amphibians. However, in the dog, Taar1 has become a
pseudogene, and in D2 mice, this non-synonymous mutation
has ablated the production of a functional receptor. It is of great
interest to us that a study in dogs found them to respond to oral
doses of d-AMPH (0.25, 0.75, 1.5mg/kg) with only hyperthermia
(Tontodonati et al., 2007). This is a trait we see in MAHDR mice
that we believe is linked to TAAR1 non-functionality, based on
information given below and in Harkness et al. (2015).
TAAR receptors belong to the family of G-protein coupled
receptors, but only TAAR1 and perhaps TAAR4 exhibit
high sensitivity to trace amines and AMPH-like compounds
(Borowsky et al., 2001; Bunzow et al., 2001). These endogenous
amine compounds are found in trace amounts, often, but not
always, in catecholaminergic systems of the mammalian nervous
system. Trace amines are viewed as intimate endogenous
neuromodulators of monoaminergic neurotransmission,
although both trace amines and AMPH-like compounds can
act on targets other than TAAR receptors (for review see Berry,
2004). When 10 MAHDR and 10 MALDR mice were sequenced
at the location of the D2 polymorphism, MAHDR mice were
found to be homozygous for the non-functional D2 Taar1 allele,
whereas MALDR were either homozygous for the alternative
functional B6 Taar1 allele or heterozygous (Harkness et al.,
2015). Thus, there is an association of the Taar1 polymorphism
with MA intake, and perhaps other MA-related traits that
differentiate the MAHDR and MALDR lines.
To further examine this relationship, Taar1 transgenic mice
were tested for MA consumption. Taar1 knockout mice, which
are homozygous for a null mutant Taar1 allele, and thus, lack
functional TAAR1, exhibited significantly higher levels of MA
intake, compared to Taar1 heterozygote or wildtype mice. In
addition, we found that functional TAAR1 increases sensitivity to
hypothermic effects of MA and toMA-induced CTA, as indicated
by higher levels of these traits in Taar1 heterozygote and wildtype
mice, compared to knockout mice. However, neither the MADR
lines, nor the transgenic genotypes, differed in sensitivity to the
hypothermic effects of ethanol (Harkness et al., 2015). Previous
data from Taar1 transgenic mice indicate altered monoaminergic
systems. For example, ventral tegmental area clamp recordings
(Lindemann et al., 2008) of DA neurons from Taar1 knockout
mice revealed significantly higher spontaneous spike frequency
and a more depolarized resting membrane potential, compared
to recordings for wildtype mice. The mean spike frequency of
DA neurons from wildtype mice was suppressed by p-tyramine,
a TAAR1 agonist, an effect that was absent in Taar1 knockout
mice. Despite these differences in firing frequencies of DA
cells, the extracellular DA and norepinephrine levels in the
striatum were the same in wildtype and Taar1 knockout mice
(Lindemann et al., 2008). Lindemann et al. (2008) suggested
that higher DA neuronal activity in Taar1 knockout mice does
not lead to higher extracellular DA release because lack of
TAAR1 activity reduces eﬄux and inhibition of DA reuptake;
in vitro studies support this view (Miller, 2011). Monoamine
reuptake transporters serve as conduits to TAAR1 substrates,
including AMPH or MA, and in turn, signals from activation
of TAAR1 inhibit monoamine uptake transporters. Furthermore,
MA can reduce cell surface monoamine uptake transporters
by as much as 70% in a TAAR1-dependent manner (Xie and
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Miller, 2009). AMPH induces significantly greater increases
in extracellular DA and norepinephrine in Taar1 knockout
than wildtype mice (Wolinsky et al., 2007; Lindemann et al.,
2008). One hypothesis is that lack of TAAR1 results in less
internalization of monoamine uptake transporters and thus,
greater monoamine uptake inhibition by AMPH or MA. In
Taar1 knockout mice, lack of tonic inhibition by TAAR1, which
translates into higher catecholaminergic activity, can lead to
quick increases in extracellular DA if uptake transporters are
blocked by AMPHorMA (Miller, 2011). Although there has been
significant recent research progress on the function of TAAR1, it
is still at a nascent stage in connecting cellular mechanisms to
behavioral effects, but see Miller (2011), Lindemann and Hoener
(2005), and Berry (2004).
Most of our recent data in Taar1 transgenic mice indicate that
the functional Taar1 allele is dominant for lowMA consumption,
sensitivity to the aversive effect of MA, and MA-induced
hypothermia (Harkness et al., 2015). Thus, mice homozygous
for the Taar1 mutant allele, exhibited a difference in phenotype,
compared to both heterozygous and homozygous mice, which
have at least one copy of the allele that produces a functional
TAAR1. We have not yet determined how heterozygous
mice differ from homozygous wildtype mice, with regard to
neurochemical traits relevant to TAAR1 function, and we do not
know whether or not twice as many functional receptors are
expressed by the wildtype vs. heterozygous mice. If that is the
case, then our data suggest that a reduction in receptor number,
even by half, does not impact these traits, and TAAR1 continues
to play a protective role.
The fold difference in MA intake between MAHDR and
MALDR mice is larger than in the progenitor strains (B6 and
D2) and the Taar1 knockout vs. wildtype mice (Harkness et al.,
2015). This could reflect the impact of genes other than Taar1
on MA drinking that were affected by selective breeding and
would be uniquely different in the oppositely selected MADR
lines. Mapping results identified additional locations of QTL for
MA drinking that had effects of smaller magnitude, compared
to the QTL on chromosome 10 (Belknap et al., 2013). However,
since the chromosome 10 QTL accounts for only approximately
half of the genetic variance in MA consumption, genes at other
locations are of interest, as are gene interactions (networks) and
the possibility that there are genes that act as “hubs.” Hubs
are genes that are highly interconnected with other genes in a
network and studies designed to manipulate such hubs and look
at phenotypic impacts are planned.
Studies in rats have examined the effects of TAAR1 agonists
on operant MA self-administration. The TAAR1 agonists,
RO5203648 and RO5263397, significantly reduced the number
of MA infusions self-administered (Cotter et al., 2015; Jing
et al., 2015). Although studies have not been done to determine
whether these agonists produce their effects by reducing the
reinforcing effects or increasing the aversive effects of MA, our
data suggest that the latter is more likely. This approach to reduce
MA consumption in the MADR mice is not possible, because
the TAAR1 in those mice is completely non-functional and an
increase in function would not be afforded by agonist treatment.
We are currently exploring human Taar1 polymorphisms to
determine what the range of TAAR1 function is in human
populations, and thus, whether the development of TAAR1
agonists is a viable consideration for MA addiction treatment.
TAAR1 appears to be essential for MA-induced hypothermic
effects. MA and AMPH are potent agonists for TAAR1
and TAAR1 is highly expressed in brain areas known for
thermoregulation, such as the preoptic area (Lindemann et al.,
2008; Morrison and Nakamura, 2011). A 20mg/kg dose of MA
dramatically increased cFos expression in the medial preoptic
area of B6 mice (Tomita et al., 2013). However, TAAR1 is
also expressed peripherally, and data do not yet exist that have
teased apart whether MA mediates thermic responses through
peripheral targets, the central nervous system or both (Broadley,
2010; Panas et al., 2012). In contrast to the results of Harkness
et al. (2015), a recent study in independently created Taar1
transgenic mice found a similar hyperthermic response to a
3mg/kg dose of MA in wildtype and Taar1 knockout mice (Panas
et al., 2010). However, the investigators did not test other doses,
such as a dose that induced hypothermia in their wildtype mice,
so it is not clear if these results are actually disparate from ours.
In addition, the method of temperature measurement in the
Harkness et al. (2015) study was via rectal probe, whereas that in
Panas et al. (2010) was via a wireless infrared thermometer over
the shaved lower back area of the mouse.
We have not examined MA-induced locomotor activation
or sensitization in our Taar1 transgenic mice; however, some
such studies exist in independently generated lines. Most of the
studies that have examined MA or AMPH effects on locomotor
activity, indicate that wildtype and Taar1 knockout mice are not
different in baseline locomotor activity, but do differ in stimulant
response, although the data have not been entirely consistent
with regard to dose-dependent differences. Thus, Taar1 knockout
mice exhibited higher locomotor activation to acute 1 and
2.5mg/kg AMPH than wildtype mice in a study by Lindemann
et al. (2008), whereas Achat-Mendes et al. (2012) observed
similar locomotor responses to 1 and 5mg/kg AMPH, but greater
activation in Taar1 knockout mice treated with 3mg/kg AMPH
or MA, compared to wildtype mice. Wolinsky et al. (2007) found
greater activation in Taar1 knockout mice in response to 1mg/kg
AMPH, but not 2.5 or 5mg/kg. But overall, Taar1 knockout mice
have exhibited greater sensitivity to AMPH-like drug stimulation.
The variability in dose responses could be related to differences
in the genetic background of the various lines. For example, both
the C57BL/6J and C57BL/6N have been used in the generation of
various knockout lines. These two strains are separated by some
220 generations; thus, their genomes have a number of variations
in their coding sequences that could influence any number of
phenotypes (Simon et al., 2013). Furthermore, spontaneous and
naturally occurring mutations in coding regions have occurred in
strains maintained by specific breeding vendors, as, for example,
for the exon deletion from Klrd1 in D2 mice coming from The
Jackson Laboratory, but not from other vendors (Shin et al.,
2015). In fact, we are currently collecting sequence data from
recombinant inbred strains derived from D2 and B6 progenitors
at different times in history that suggest the Taar1 non-functional
allele may be a newer spontaneously occurring mutation in the
D2 strain.
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Conclusions and Future Directions
MADR mice provide a unique opportunity to further explore
the contribution of Taar1 and TAAR1 to voluntary MA
consumption, and to the acute and repeated MA-related effects
that are genetically correlated with consumption and also seem
to be regulated by this gene and its receptor. Decades of research
on genetic risk for alcoholism has led to the conclusion that rare
single gene variants with large impacts might still be found, but
that common variants in multiple genes, each with a small effect,
are those more likely to be implicated (Enoch, 2013). Less is
known about the genetic architecture of risk for MA abuse, and
the large effect QTL found in our selected lines could represent
the impact of a rare variant. Genetic investigation in humans is
needed to address this question. However, a gene or genes in
the chromosome 10 QTL region accounts for about half of the
genetic variance in the MA consumption trait, thus, additional
research is needed to examine the impact of other genes and
how they interact to increase risk for MA use. We are currently
developing a binge model of MA intake using the MAHDR
line and studying how differing periods of withdrawal from
chronic MA use might impact their drinking behavior. These
and other studies are intended to improve our genetic model
with regard to its translational value to human addiction. In this
way, important mechanisms may be identified, with druggable
targets, for the development of pharmacotherapeutics for MA
abuse. Another important future direction is to determine the
impact of the Taar1 mutation on MA-related traits on different
genetic backgrounds and to study whether there are epistatic
(gene × gene) or gene × environment interactions that impact
the effect of the Taar1mutation.
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